85 results
Page 3 of 5
8-K
EX-99.1
ufh6l 84tadq1
26 Feb 21
BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update
6:03am
8-K
EX-1.1
2zk0b4w6wmqtqkjvt2
17 Feb 21
Entry into a Material Definitive Agreement
4:16pm
424B7
ggry q5sfj
16 Feb 21
Prospectus with selling stockholder info
5:24pm
424B7
15sqc8 05z
11 Feb 21
Prospectus with selling stockholder info
5:15pm
8-K
EX-10.1
aqog o5beiy
29 Jan 21
Entry into a Material Definitive Agreement
7:07am
8-K
EX-10.1
xwhsac04v 4lssah
26 Jan 21
BridgeBio Pharma, Inc. Announces Proposed Offering of $400 Million Convertible Senior Notes
4:56pm
DEFM14A
1ket78e3rqv4 9k
15 Dec 20
Proxy related to merger
9:26am
424B3
ucw t35h3d
15 Dec 20
Prospectus supplement
9:22am
S-4/A
nj25jw3307an zssi32
11 Dec 20
Registration of securities issued in business combination transactions (amended)
7:11am
S-4
dgv1t
6 Nov 20
Registration of securities issued in business combination transactions
5:05pm
S-4
EX-99.3
f0ns54w
6 Nov 20
Registration of securities issued in business combination transactions
5:05pm
8-K
EX-99.1
xx1n5g4d8ktu9j
5 Nov 20
BridgeBio Pharma, Inc. Reports Third Quarter 2020 Financial Results And Business Update
8:00am
425
oocu061egel33
5 Oct 20
Business combination disclosure
9:58pm
8-K
EX-99.1
2vsg urllcw
5 Oct 20
Bridgebio Pharma and Eidos Therapeutics Announce Merger Agreement
5:19pm
425
EX-99.1
knn1yk27kh2 b40oe7
5 Oct 20
Business combination disclosure
5:17pm